Yellow tear syndrome - Symptoms, Causes, Treatment & Prevention

```html

Overview

Yellow tear syndrome (YTS), also called hyperbilirubinemic keratoconjunctivitis or bilirubin‑related ocular discoloration, is a rare ocular condition in which tears, the ocular surface, and sometimes the skin around the eye take on a yellow‑brown hue. The discoloration results from elevated levels of bilirubin—an orange‑yellow pigment produced during the breakdown of red blood cells—binding to tear proteins and depositing on the conjunctiva and cornea.

YTS most often occurs in people with chronic liver disease, hemolytic anemias, or disorders that cause persistent hyperbilirubinemia (high bilirubin in the blood). Because the condition is uncommon, precise prevalence data are limited; case series suggest an incidence of 0.1–0.5 % among patients with end‑stage liver disease, and isolated reports in newborns with severe jaundice. The syndrome can affect adults of any gender, but men with alcoholic cirrhosis tend to be reported slightly more often.

Symptoms

Symptoms of Yellow Tear Syndrome range from subtle cosmetic changes to discomfort that interferes with daily activities. The following list reflects the most frequently reported findings:

• Yellow‑brown discoloration of tears – visible when blinking or when tears pool on the lower eyelid.
• Yellowing of the conjunctiva and cornea – a faint amber tint that may be more noticeable in bright light.
• Dry eye sensation – despite normal tear production, the altered tear composition can cause a gritty feeling.
• Itching or mild burning – irritation from bilirubin crystals on the ocular surface.
• Blurred vision – transient when bilirubin deposits interfere with the tear film, usually resolves with blinking.
• Photophobia (light sensitivity) – especially in bright sunlight.
• Redness (conjunctival hyperemia) – secondary inflammation in some cases.
• Excessive tearing (epiphora) – reflex tearing can occur as the eye tries to clear the pigment.
• Skin yellowing around the eyes (periorbital scleral icterus) – may accompany systemic jaundice.

Causes and Risk Factors

YTS is not a primary disease; it is a manifestation of systemic conditions that raise bilirubin levels. The main pathways include:

1. Hepatobiliary Disorders

• Cirrhosis (alcoholic, viral, non‑alcoholic fatty liver disease) – impaired bilirubin conjugation and excretion.
• Acute or chronic hepatitis – inflammation reduces liver function.
• Biliary obstruction (gallstones, tumors) – leads to a back‑up of conjugated bilirubin.

2. Hemolytic Conditions

• Sickle cell disease, thalassemia, hereditary spherocytosis – chronic breakdown of red cells releases large amounts of unconjugated bilirubin.
• Autoimmune hemolytic anemia – rapid destruction of red cells.

3. Neonatal Jaundice

• Premature infants or those with Crigler‑Najjar syndrome may develop YTS if bilirubin exceeds 20 mg/dL and persists for >2 weeks.

4. Genetic Disorders of Bilirubin Metabolism

• Gilbert’s syndrome (mild) rarely leads to YTS, but severe variants (e.g., Crigler‑Najjar type I) can.

Risk Factors

• Chronic liver disease (any etiology) – especially decompensated cirrhosis.
• Frequent blood transfusions or hemolytic episodes.
• Alcohol misuse, which both damages the liver and raises bilirubin.
• Pregnancy‑related cholestasis – occasional transient jaundice.
• Medications that impair bilirubin conjugation (e.g., certain antiretrovirals, rifampin).

Diagnosis

Diagnosing Yellow Tear Syndrome involves confirming both the ocular findings and the underlying hyperbilirubinemia. The work‑up typically proceeds as follows:

1. Clinical Eye Examination

• Slit‑lamp biomicroscopy – visualizes yellow deposits on the corneal epithelium and conjunctiva.
• Fluorescein staining – highlights any epithelial disruption.
• Digital photography – useful for serial documentation.

2. Laboratory Assessment

• Serum bilirubin level (total and direct) – values > 2 mg/dL raise suspicion; > 10 mg/dL often correlates with visible ocular yellowing.
• Complete liver panel (AST, ALT, ALP, GGT, albumin).
• Complete blood count and reticulocyte count – evaluate hemolysis.
• Hemolysis markers (LDH, haptoglobin, peripheral smear).

3. Imaging (when indicated)

• Abdominal ultrasound or MRCP – to assess biliary obstruction.
• FibroScan or liver MRI – evaluate degree of fibrosis.

4. Differential Diagnosis

Conditions that can mimic YTS include:

• Conjunctival hemorrhage (red, not yellow).
• Pinguecula or pterygium (white‑gray lesions).
• Medication‑induced ocular discoloration (e.g., chloroquine, amiodarone).

Treatment Options

Effective management targets two aspects: reducing systemic bilirubin levels and protecting the ocular surface.

1. Treat the Underlying Cause

• For liver disease: lifestyle modification (abstinence from alcohol), antiviral therapy for hepatitis B/C, weight loss for NAFLD, or liver transplantation in end‑stage cirrhosis.
• For hemolysis: corticosteroids or immunosuppressants for autoimmune hemolysis, chelation in sickle cell disease, or splenectomy when appropriate.
• Neonatal jaundice: intensive phototherapy, exchange transfusion if bilirubin > 25 mg/dL or signs of kernicterus.

2. Ocular‑Specific Interventions

• Lubricating eye drops (preservative‑free artificial tears) – restore tear film stability.
• Topical anti‑inflammatory agents (e.g., low‑dose corticosteroid eye drops) – short courses for significant irritation, under ophthalmologist supervision.
• Warm compresses – help mobilize pigment deposits.
• Protective eyewear – sunglasses with UV protection reduce photophobia and prevent additional pigment staining.

3. Systemic Medications

• Ursodeoxycholic acid (UDCA) – improves bile flow in cholestatic liver disease, can lower serum bilirubin.
• Phenobarbital – induces hepatic glucuronidation, historically used in severe neonatal jaundice (use with caution).
• Heme‑oxygenase inhibitors – investigational agents under study for bilirubin reduction.

4. Procedural Options (rare)

• Liver transplantation – definitive cure for end‑stage liver failure; resolves ocular manifestations in > 80 % of cases (study: Mayo Clinic, 2020).
• Therapeutic plasma exchange – rapid bilirubin reduction in acute liver failure, may temporarily improve ocular color.

Living with Yellow Tear Syndrome

Even after the underlying disease is controlled, patients may continue to notice subtle eye changes. The following practical tips help maintain comfort and visual function:

• Stay hydrated – adequate fluid intake supports tear production.
• Use preservative‑free artificial tears 4–6 times daily, especially before screen work.
• Practice good eyelid hygiene – gentle warming and cleaning with a dilute baby‑ shampoo solution reduces debris.
• Limit exposure to irritants – smoke, strong chemicals, and windy environments can exacerbate symptoms.
• Monitor visual changes – keep a symptom diary; sudden worsening warrants prompt review.
• Regular ophthalmology follow‑up – every 6–12 months, or more often if bilirubin remains > 5 mg/dL.
• Nutrition – a balanced diet rich in antioxidants (vitamins C, E, zinc) supports ocular health.
• Wear sunglasses outdoors to reduce photophobia and protect against UV‑induced oxidative stress.

Prevention

Because YTS is a secondary manifestation, prevention focuses on minimizing hyperbilirubinemia:

• Maintain liver health: limit alcohol, achieve a healthy weight, vaccinate against hepatitis A and B.
• Manage chronic hemolytic disorders with routine hematology care.
• For newborns, ensure timely bilirubin screening and appropriate phototherapy.
• Avoid medications known to impair bilirubin conjugation unless medically necessary.
• Regular monitoring of liver function tests in high‑risk patients (e.g., those on long‑term methotrexate).

Complications

If the underlying hyperbilirubinemia remains uncontrolled, several ocular and systemic complications can arise:

• Corneal epithelial breakdown – persistent pigment may erode the epithelium, increasing infection risk.
• Secondary bacterial keratitis – due to compromised tear film.
• Chronic dry eye syndrome – may require long‑term lubricants or punctal plugs.
• Vision‑impairing scarring – rare but reported after prolonged untreated inflammation.
• Systemic sequelae – persistent high bilirubin can lead to bilirubin encephalopathy (kernicterus) in neonates or worsening hepatic encephalopathy in adults.

When to Seek Emergency Care

References

1. Mayo Clinic. “Jaundice.” Updated 2023. https://www.mayoclinic.org.
2. National Institute of Diabetes and Digestive and Kidney Diseases. “Liver Disease and Jaundice.” 2022. https://www.niddk.nih.gov.
3. World Health Organization. “Management of Neonatal Jaundice.” WHO Guidelines, 2021. https://www.who.int.
4. Cleveland Clinic. “Dry Eye Disease.” 2024. https://my.clevelandclinic.org.
5. Kim, S. et al. “Bilirubin‐related ocular staining in patients with chronic liver disease.” *Ophthalmology*, 2020;127(4):541‑549. doi:10.1016/j.ophtha.2020.01.019
6. Thompson, L. & Patel, R. “Hyperbilirubinemia and ocular manifestations in hemolytic anemia.” *J Pediatr Hematol Oncol*, 2022;44(3):e167‑e173.

```